Scott Rosenberg, MD
Pulmonary Disease · Woodbury, NJNPI 1063461614
Payments from drug & device makers
Across 502 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Sanofi$679
- Regeneron Healthcare Solutions, Inc.$483
- Jazz Pharmaceuticals Inc.$446
- Genentech USA, Inc.$330
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,57499%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 131 | $1,584 |
| AstraZeneca | 72 | $1,177 |
| Sanofi | 45 | $679 |
| Regeneron Healthcare Solutions, Inc. | 28 | $483 |
| Jazz Pharmaceuticals Inc. | 29 | $446 |
| Genentech USA, Inc. | 19 | $330 |
| Harmony Biosciences LLC | 18 | $318 |
| Boehringer Ingelheim | 18 | $298 |
| Amgen | 10 | $203 |
| Grifols USA, LLC | 11 | $198 |
| Philips North America LLC | 12 | $191 |
| Insmed, Inc. | 12 | $168 |
| Verona Pharma, Inc. | 11 | $168 |
| United Therapeutics Corporation | 10 | $148 |
| Actelion Pharmaceuticals US, Inc. | 10 | $141 |
| Avadel CNS Pharmaceuticals, LLC | 6 | $111 |
| Axsome Therapeutics, Inc. | 7 | $107 |
| Novartis | 6 | $98 |
| Electromed, Inc. | 7 | $95 |
| Inspire Medical Systems, Inc. | 4 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $85 |
| Teva Pharmaceuticals USA, Inc. | 6 | $84 |
| Pfizer | 4 | $62 |
| Sanofi Pasteur Inc. | 4 | $54 |
| Sanofi-aventis U.S. LLC | 1 | $46 |
| Mylan Specialty L.p. | 3 | $45 |
| ANI Pharmaceuticals, Inc. | 2 | $42 |
| Resmed Corp | 2 | $40 |
| Bayer | 2 | $36 |
| Pulmonx Corporation | 1 | $29 |
| Vapotherm Inc | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Merck | 1 | $14 |
How this compares
$7,665 in reported general payments places this provider in the 75th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 35 | $528,960 |
| OfevNintedanib Esylate | 20 | $259,324 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 255 | $239,607 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 164 | $103,772 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 81 | $85,608 |
| XolairOmalizumab | 23 | $78,418 |
| NucalaMepolizumab | 13 | $55,697 |
| Incruse ElliptaUmeclidinium Bromide | 94 | $49,007 |
| Breo ElliptaFluticasone/Vilanterol | 77 | $48,350 |
| Pirfenidone | 13 | $35,335 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 41 | $23,679 |
| Spiriva RespimatTiotropium Bromide | 16 | $15,681 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 277 | $13,434 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $13,243 |
| BelsomraSuvorexant | 20 | $10,119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Incruse Ellipta, Breo Ellipta | $1,584 | $503,393623 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $298 | $298,68477 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,177 | $104,397126 claims |
| MerckBelsomra | $14 | $10,11920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Woodbury
- Gregory BreenWoodbury$29K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.